Skip to main content
Top
Published in: Annals of Nuclear Medicine 2/2019

01-02-2019 | Original Article

[99mTc]3PRGD2 for integrin receptor imaging of esophageal cancer: a comparative study with [18F]FDG PET/CT

Authors: Shan Zheng, Zhenying Chen, Chao Huang, Yun Chen, Weibing Miao

Published in: Annals of Nuclear Medicine | Issue 2/2019

Login to get access

Abstract

Objectives

This study was designed to investigate the efficacy of 99mtechnetium-three polyethylene glycol spacers-arginine–glycine–aspartic acid ([99mTc]3PRGD2) in the evaluation of patients with esophageal cancer.

Methods

Twenty-nine patients with a suspected esophageal lesion and for whom definite pathological diagnosis was finally obtained were recruited. Whole-body planar scanning and chest single-photon-emission computed tomography/computed tomography (SPECT/CT) were performed at 30 and 40 min, respectively, after intravenous injection of 11.1 MBq/kg of [99mTc]3PRGD2. 2-Deoxy-2-[18F] fluoro-d-glucose ([18F]FDG) positron-emission tomography/computed tomography (PET/CT) was performed in 1 week. The tumor-to-background ratio (T/B) and the maximum standard uptake value (SUVmax) were calculated for semi-quantitative and quantitative analyses. Integrin αvβ3 was analyzed through immunohistochemistry.

Results

The T/B, SUVmax and expression of integrin αvβ3 in malignant lesions were higher than those in benign lesions (t = 3.691, P = 0.001; t = 8.271, P = 0.000; t = 3.632, P = 0.001, respectively). There was a significant correlation between T/B and SUVmax in esophageal lesions (r = 0.660, P = 0.000). The expression of integrin αvβ3 was correlated with [99mTc]3PRGD2 uptake (r = 0.782, P = 0.000). In visual analysis, the sensitivity and accuracy of the whole-body planar RGD scan were lower than those of the chest SPECT/CT RGD scan and the [18F]FDG PET/CT scan (x2 = 6.769, P = 0.022). The sensitivity, specificity and accuracy of the chest SPECT/CT RGD scan were similar to those of the [18F] FDG PET/CT scan. In semi-quantitative analysis, the sensitivity, specificity and accuracy of chest SPECT/CT RGD from the receiver operating characteristic (ROC) analysis were 87%, 100% and 94%, respectively [cutoff = 3.1 of T/B, area under the curve (AUC) = 0.957]. Thirteen patients (30 lymph nodes) and 16 patients (105 lymph nodes) were suspected to have lymph node metastases based on the RGD and FDG scans, respectively.

Conclusion

This prospective study demonstrated that [99mTc]3PRGD2 imaging is valuable for the diagnosis and staging of esophageal cancer. It may be less sensitive than [18F]FDG imaging for detecting metastatic lesions in small lymph nodes. The T/B value was correlated with the expression of integrin αvβ3.

NIH ClinicalTrials.gov

NCT 02744729.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef
2.
go back to reference Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB, et al. Esophageal cancer: the five year survivors. J Surg Oncol. 2011;103:179–83.CrossRefPubMed Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB, et al. Esophageal cancer: the five year survivors. J Surg Oncol. 2011;103:179–83.CrossRefPubMed
3.
go back to reference Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011;29:868–74.CrossRefPubMed Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011;29:868–74.CrossRefPubMed
5.
go back to reference Pasini F, Fraccon AP, Modena Y, Bencivenga M, Giacopuzzi S, La Russa F, et al. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new? Gastric Cancer. 2017;20:31–42.CrossRefPubMed Pasini F, Fraccon AP, Modena Y, Bencivenga M, Giacopuzzi S, La Russa F, et al. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new? Gastric Cancer. 2017;20:31–42.CrossRefPubMed
6.
go back to reference Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, et al. Positron emission tomography using [18F] galacto-RGD identifies the level of integrin αvβ3 expression in man. Clin Cancer Res. 2006;12:3942–9.CrossRefPubMed Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, et al. Positron emission tomography using [18F] galacto-RGD identifies the level of integrin αvβ3 expression in man. Clin Cancer Res. 2006;12:3942–9.CrossRefPubMed
7.
go back to reference Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ, et al. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent [99mTc]-NC100692. Acta Radiol. 2010;51:40–6.CrossRefPubMed Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ, et al. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent [99mTc]-NC100692. Acta Radiol. 2010;51:40–6.CrossRefPubMed
8.
go back to reference Wang L, Shi J, Kim YS, Zhai S, Jia B, Zhao H, et al. Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers. Mol Pharm. 2009;6:231–45.CrossRefPubMedPubMedCentral Wang L, Shi J, Kim YS, Zhai S, Jia B, Zhao H, et al. Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers. Mol Pharm. 2009;6:231–45.CrossRefPubMedPubMedCentral
9.
go back to reference Jia B, Liu Z, Zhu Z, Shi J, Jin X, Zhao H, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulate integrin αvβ3-selective radiotracer [99mTc]3PRGD2 in non-human primates. Mol Imaging Biol. 2011;13:730–6.CrossRefPubMed Jia B, Liu Z, Zhu Z, Shi J, Jin X, Zhao H, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulate integrin αvβ3-selective radiotracer [99mTc]3PRGD2 in non-human primates. Mol Imaging Biol. 2011;13:730–6.CrossRefPubMed
10.
go back to reference Zhu Z, Miao W, Li Q, Dai H, Ma Q, Wang F, et al. [99mTc]3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med. 2012;53:716–22.CrossRefPubMed Zhu Z, Miao W, Li Q, Dai H, Ma Q, Wang F, et al. [99mTc]3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med. 2012;53:716–22.CrossRefPubMed
11.
go back to reference Miao W, Zheng S, Dai H, Wang F, Jin X, Zhu Z, et al. Comparison of [99mTc]3PRGD2 integrin receptor imaging with [99mTc]MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study. PLoS One. 2014;9:e111221.CrossRefPubMedPubMedCentral Miao W, Zheng S, Dai H, Wang F, Jin X, Zhu Z, et al. Comparison of [99mTc]3PRGD2 integrin receptor imaging with [99mTc]MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study. PLoS One. 2014;9:e111221.CrossRefPubMedPubMedCentral
12.
go back to reference Chen Q, Xie Q, Zhao M, Chen B, Gao S, Zhang H, et al. Diagnostic value of [99mTc]3PRGD2 scintimammography for differentiation of malignant from benign breast lesions: comparison of visual and semi-quantitative analysis. Hell J Nucl Med. 2015;18:193–8.PubMed Chen Q, Xie Q, Zhao M, Chen B, Gao S, Zhang H, et al. Diagnostic value of [99mTc]3PRGD2 scintimammography for differentiation of malignant from benign breast lesions: comparison of visual and semi-quantitative analysis. Hell J Nucl Med. 2015;18:193–8.PubMed
13.
go back to reference Huang C, Zheng Q, Miao W. Study of novel molecular probe [99mTc]3PRGD2 in the diagnosis of rheumatoid arthritis. Nucl Med Commun. 2015;36:1208–14.CrossRefPubMed Huang C, Zheng Q, Miao W. Study of novel molecular probe [99mTc]3PRGD2 in the diagnosis of rheumatoid arthritis. Nucl Med Commun. 2015;36:1208–14.CrossRefPubMed
14.
go back to reference Liu Z, Jia B, Shi J, Jin X, Zhao H, Li F, et al. Tumor uptake of the RGD dimeric probe [99mTc]-G3-2P4-RGD2 is correlated with integrin expressed on both tumor cells and neovasculature. Bioconjug Chem. 2010;21:548–55.CrossRefPubMed Liu Z, Jia B, Shi J, Jin X, Zhao H, Li F, et al. Tumor uptake of the RGD dimeric probe [99mTc]-G3-2P4-RGD2 is correlated with integrin expressed on both tumor cells and neovasculature. Bioconjug Chem. 2010;21:548–55.CrossRefPubMed
15.
go back to reference Ma Q, Chen B, Gao S, Ji T, Wen Q, Song Y, et al. [99mTc]-3P4-RGD2 scintimammography in the assessment of breast lesions: comparative study with [99mTc] MIBI. PLoS One. 2014;9:e108349.CrossRefPubMedPubMedCentral Ma Q, Chen B, Gao S, Ji T, Wen Q, Song Y, et al. [99mTc]-3P4-RGD2 scintimammography in the assessment of breast lesions: comparative study with [99mTc] MIBI. PLoS One. 2014;9:e108349.CrossRefPubMedPubMedCentral
16.
go back to reference Zhao D, Jin X, Li F, Liang J, Lin Y, et al. Integrin αvβ3 imaging of radioactive iodine–refractory thyroid cancer using [99mTc]3PRGD2. J Nucl Med. 2012;53:1872–7.CrossRefPubMed Zhao D, Jin X, Li F, Liang J, Lin Y, et al. Integrin αvβ3 imaging of radioactive iodine–refractory thyroid cancer using [99mTc]3PRGD2. J Nucl Med. 2012;53:1872–7.CrossRefPubMed
17.
go back to reference Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst. 2005;97:172–87.CrossRefPubMed Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst. 2005;97:172–87.CrossRefPubMed
18.
go back to reference Cai W, Rao J, Gambhir SS, Chen X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006;5:2624–33.CrossRefPubMed Cai W, Rao J, Gambhir SS, Chen X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006;5:2624–33.CrossRefPubMed
19.
go back to reference Niu G, Chen X. Has molecular and cellular imaging enhanced drug discovery and drug development. Drugs R D. 2008;9:351–68.CrossRefPubMed Niu G, Chen X. Has molecular and cellular imaging enhanced drug discovery and drug development. Drugs R D. 2008;9:351–68.CrossRefPubMed
Metadata
Title
[99mTc]3PRGD2 for integrin receptor imaging of esophageal cancer: a comparative study with [18F]FDG PET/CT
Authors
Shan Zheng
Zhenying Chen
Chao Huang
Yun Chen
Weibing Miao
Publication date
01-02-2019
Publisher
Springer Singapore
Published in
Annals of Nuclear Medicine / Issue 2/2019
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-018-1315-3

Other articles of this Issue 2/2019

Annals of Nuclear Medicine 2/2019 Go to the issue

Acknowledgment to Reviewers

Acknowledgements to reviewers